Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Marija Trajkovic‐Arsic

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0791-0248; OpenAlex author ID A5051602756, A5108832978. Sources: OpenAlex.

Their work

Papers
30 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
109
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 4 papers · 2026: 2 papers

Papers 30

  1. Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-026-69013-y↗
  2. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  3. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. Co-author DOI 10.1002/1878-0261.13747↗
  4. Correction to: Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine‑induce… First author DOI 10.1007/s00259-025-07195-1↗
  5. PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2025.115541↗
  6. Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08979-z↗
  7. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  8. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. Co-author DOI 10.1186/s13148-024-01623-z↗
  9. Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer. First author DOI 10.2967/jnumed.123.266262↗
  10. Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acs.molpharmaceut.3c00453↗
  11. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05728-y↗
  12. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth. Co-author DOI 10.1158/1078-0432.ccr-22-0794↗
  13. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascular… First author DOI 10.1007/s00259-022-05930-6↗
  14. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40170-022-00298-5↗
  15. Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2021.07.23.452145↗
  16. Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13550-021-00862-y↗
  17. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33137↗
  18. TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Co-author DOI 10.1038/s41420-020-0246-7↗
  19. MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In Vivo. Co-author DOI 10.1155/2019/8475389↗
  20. A Novel Approach for Image-Guided 131I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery. Co-author DOI 10.1158/1541-7786.mcr-18-0185↗
  21. Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting. Co-author DOI 10.1158/0008-5472.can-18-0052↗
  22. Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-017-16826-z↗
  23. Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-2432↗
  24. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene. Co-author DOI 10.18632/oncotarget.16499↗
  25. Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model. Co-author DOI 10.1016/j.ajpath.2016.07.025↗
  26. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.3952↗
  27. Multimodal molecular imaging of integrin αvβ3 for in vivo detection of pancreatic cancer. Co-author DOI 10.2967/jnumed.113.129619↗
  28. X-ray phase-contrast CT of a pancreatic ductal adenocarcinoma mouse model. Co-author DOI 10.1371/journal.pone.0058439↗
  29. The role of insulin and IGF system in pancreatic cancer. Co-author DOI 10.1530/jme-12-0259↗
  30. MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0039424↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jens Thomas Siveke · 30 shared papers, 2012–2026 · strength 3.37
  2. Rickmer Braren · 14 shared papers, 2013–2026 · strength 1.53
  3. Phyllis F. Cheung · 8 shared papers, 2018–2026 · strength 1.01
  4. Irina Heid · 9 shared papers, 2015–2026 · strength 1.00
  5. Stephan A. Hahn · 8 shared papers, 2015–2026 · strength 0.96
  6. Laura Godfrey · 5 shared papers, 2021–2026 · strength 0.77
  7. Smiths Lueong · 5 shared papers, 2020–2025 · strength 0.70
  8. Iréne Esposito · 8 shared papers, 2012–2026 · strength 0.67
  9. Sven‐Thorsten Liffers · 5 shared papers, 2018–2026 · strength 0.63
  10. Erik H.J.G. Aarntzen · 4 shared papers, 2021–2024 · strength 0.56
  11. E. Smeets · 4 shared papers, 2021–2024 · strength 0.56
  12. Wilko Weichert · 4 shared papers, 2021–2025 · strength 0.54
  13. Roland Michael Schmid · 7 shared papers, 2012–2026 · strength 0.54
  14. Aldo Scarpa Scarpa · 3 shared papers, 2023–2026 · strength 0.51
  15. Jorg H. Kleeff · 6 shared papers, 2012–2026 · strength 0.49
  16. Diana Behrens · 3 shared papers, 2020–2026 · strength 0.47
  17. Mert Erkan · 4 shared papers, 2015–2026 · strength 0.43
  18. Bence Sipos · 4 shared papers, 2015–2026 · strength 0.43
  19. Hendrik Schürmann · 2 shared papers, 2025 · strength 0.40
  20. Pawel Karol Mazur · 4 shared papers, 2012–2026 · strength 0.40
  21. Jörg D. Hoheisel · 3 shared papers, 2021–2025 · strength 0.40
  22. Stephano S. Mello · 3 shared papers, 2015–2026 · strength 0.37
  23. Julien Sage · 3 shared papers, 2015–2026 · strength 0.37
  24. Alexander Herner · 3 shared papers, 2015–2026 · strength 0.37
  25. Elisabeth Heßmann · 3 shared papers, 2015–2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.